Immunovia Publishes Full Year Report for 2023
October-December 2023 · Net sales, which for the quarter only included royal- ties, amounted to kSEK 155 (502). · Net earnings were MSEK -49 (-67) and earnings per share before and after dilution were SEK -1.08 (-2.97). · Cash Flow from operating activities amount MSEK -28 (-51). · Cash and equivalents at the end of the period amounted to MSEK 77 (106). · On October 3, the Company announced that the Nomination Committee had been appointed to consist of the following persons who together represent 7,52 percent of the total number of outstanding shares and votes in the